CARDAMYST is the brand name for etripamil nasal spray, FDA-approved for adults with acute symptomatic PSVT to restore normal rhythm. It is a prescribed episode treatment after the rhythm and suitability have been established.
Discover Nao Medical's virtual care solutions for occupational health. From wellness checkups to mental health support, boost productivity with care from anywhere.
CARDAMYST is the brand name for etripamil nasal spray, FDA-approved for adults with acute symptomatic PSVT to restore normal rhythm. It is a prescribed episode treatment after the rhythm and suitability have been established. It is not a general remedy for a racing heart or a replacement for emergency assessment of severe symptoms.
Etripamil blocks calcium channels and acts on cardiac conduction. It differs from other nasal medicines and is not verapamil. PSVT, atrial fibrillation and other causes of palpitations are different diagnoses. A clinician must establish when the rescue plan applies and when another form of care is necessary.
The label excludes specified heart conditions, including moderate to severe heart failure, certain pre-excitation syndromes, sick sinus syndrome without a permanent pacemaker and second-degree or higher AV block. A history of low blood pressure or fainting requires review. Safety and effectiveness in children are not established.
Discuss documented PSVT, prior episodes, cardiology recommendations and medicines. If prescribed, the clinician explains device use, sitting precautions and the emergency plan. Follow the supplied patient information. A visit does not guarantee prescription eligibility, successful rhythm conversion or a need for this option rather than another treatment.
Bring rhythm records and a full medicine list. Discuss pregnancy and breastfeeding. Learn the technique before an episode occurs and check the device's expiration and replacement process. The label says not to prime or test the device; do not use it for another person's symptoms.
Use the medicine only under the prescribed plan. Call 911 immediately for severe symptoms such as chest pain, fainting or major breathing difficulty. Etripamil can cause dizziness and fainting, so use it seated in a safe place. The label requires medical contact or emergency help if symptoms do not improve within 20 minutes after a second dose; severe symptoms require earlier action.
Tell the treating clinician about response, persistent symptoms and side effects. The label directs a 12-hour interruption of breastfeeding after use with pumping and discarding milk; discuss an infant-feeding plan beforehand. Review recurrent episodes with cardiology rather than treating them indefinitely without follow-up.
The current approval does not verify Nao prescribing, pharmacy supply or exact-plan coverage. Confirm the assessment pathway and availability. Patient forum interest identifies questions about a new rescue option and when to use it, not evidence that it is appropriate for an undiagnosed episode.
Yes. The clinician needs evidence that the episodes are PSVT rather than another rhythm problem, using the ECG or rhythm recordings and your history. Bring prior ECGs, monitor reports, cardiology notes and a medicine list. A symptom description or smartwatch alert alone does not establish that Cardamyst is appropriate.
No. Cardamyst contains etripamil, a calcium-channel blocker delivered by nasal spray. It is a different medicine from verapamil; doses and products are not interchangeable. Use only the prescribed product and the clinician's PSVT rescue plan.
Cardamyst (etripamil) is labeled for adults with diagnosed paroxysmal supraventricular tachycardia, or PSVT. It is not a rescue medicine for atrial fibrillation or any unexplained racing heartbeat. A clinician must confirm the rhythm and assess safety before prescribing it. Severe chest pain, breathing difficulty or fainting needs emergency help.
No. A rescue medicine does not replace emergency care for severe symptoms or cardiology review of recurrent episodes. Your cardiologist should discuss monitoring, preventive treatment and whether catheter ablation is appropriate. Keep an explicit plan for an episode that persists despite the prescribed rescue doses.
Follow the prescribed rescue and emergency plan. The Cardamyst label says to seek medical help if symptoms do not improve within 20 minutes after the second dose. Call 911 immediately for severe chest pain, breathing difficulty, fainting or other severe symptoms instead of waiting for that interval. Do not keep taking extra doses beyond the prescribed instructions.
Before home use, the clinician should confirm PSVT, review heart and blood-pressure conditions and interacting medicines, teach the exact administration steps and set an emergency plan. Bring prior rhythm records. Confirm how to reach the prescribing team and what to do if the episode persists. A prescription does not establish local pharmacy supply.
Etripamil is FDA-approved as CARDAMYST nasal spray for conversion of acute symptomatic PSVT episodes to normal rhythm in adults. Its initial U.S. approval was in 2025. Approval does not establish current pharmacy supply, insurance authorization or a Nao prescribing service. Ask your cardiology team whether it fits your confirmed rhythm diagnosis and contraindications, then check the actual dispensing route. It is not for every racing heart or atrial fibrillation. Severe chest pain, breathing difficulty or fainting needs emergency help regardless of a prescription or supply delay.
Choose care according to the problem and how urgently you need help. Urgent care assesses non-emergency illnesses and minor injuries.
